Research projects

Tracking environmental causes of Lewy body disease using DNA methylation profiling
Postdoctoral fellowship project - Funded by the South-Eastern Norway Regional Health Authority 2025

NAD-HD: A randomized clinical trial of nicotinamide riboside in Huntington’s disease
Funded by KLINBEFORSK and the South-Eastern Norway Regional Health Authority 2024

NAD-HDx: Participant experiences and exploratory outcomes in a randomized clinical trial of nicotinamide riboside in Huntington’s disease
Funded by the Dam Foundation 2024

Understanding neuroinflammation in Parkinson’s disease using single-cell multiomics
Postdoctoral fellowship project - Funded by the South-Eastern Norway Regional Health Authority 2023

Mapping and measuring gene dysregulation for precision medicine in PD
Postdoctoral fellowship project - Funded by the South-Eastern Norway Regional Health Authority 2022

Pathway-specific polygenic risk scores: Linking molecular mechanisms to clinical outcomes in Parkinson's disease
Funded by the Michael J. Fox Foundation 2021

Parkinsonism from the young to the aging: Leveraging genomics for precision medicine
Career fellowship project - Funded by the South-Eastern Norway Regional Health Authority 2021

Polygenic risk in neurodegenerative disease: disentangling mechanisms and facilitating precision medicine
Postdoctoral fellowship project - Funded by the South-Eastern Norway Regional Health Authority 2020

Linking genetics and protein pathology in Parkinson's disease: α-synuclein and β-amyloid
PhD fellowship project - Funded by the South-Eastern Norway Regional Health Authority 2019

Methylation of the SNCA and GBA loci in Parkinson's disease
With PI Mathias Toft of the Molecular studies of Parkinson's disease group - Funded by the Michael J. Fox Foundation 2017

Genomic approaches to neuroinflammation in disorders of Parkinsonism
PhD fellowship project - Funded by the South-Eastern Norway Regional Health Authority 2017

Mapping the epigenetics of Lewy body dementias
Postdoctoral fellowship project - Funded by the Norwegian Health Association 2016

NAD-HD is a double-blind randomized controlled multicenter trial investigating the effect of nicotinamide riboside supplement as a potential disease-modifying treatment in Huntington’s disease. The study has received funding from the KLINBEFORSK program, South-Eastern Norway Regional Health Authority and the Dam Foundation, and was launched in 2025 and is currently recruiting participants at Oslo University Hospital. A second study site will open in Bergen. Collaboration with patient organizations is also be central to the project.

Prospective study of parkinsonism in Oslo (PROSPOS) is a  longitudinal observational study tracking natural history, genetics, and biomarkers to understand disease mechanisms and facilitate personalized medicine in Parkinson’s disease and atypical parkinsonism, including multiple system atrophy (MSA). This study forms the basis of a number of ongoing PhD projects involving methods such as brain imaging using PET and MRI, studies of cerebrospinal fluid biomarkers, single-cell sequencing analyses and eye-tracking technology.

Enroll-HD is a global registry for Huntington’s disease including both symptomatic and presymptomatic gene carriers as well as family and community controls. Data is collected at annual visits. The study has included more than 30,000 participants worldwide. 

NADAPT is a double-blind randomized controlled trial investigating nicotinamide riboside supplement as a potential disease-modifying treatment in atypical parkinsonism, including multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). The trial is led from the Haukeland University Hospital and the NeuroSysMed center. Lasse Pihlstrøm is site-PI at Oslo University Hospital

NOPARK was a double-blind randomized controlled trial investigating nicotinamide riboside supplement as a potential disease-modifying treatment in Parkinson’s disease. The trial was led from the Haukeland University Hospital and the NeuroSysMed center and was completed in 2025. Lasse Pihlstrøm was site-PI at Oslo University Hospital